Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
In the year-ago quarter, the company reported a loss of 69 cents. ALLO recorded revenues of $0.02 million during the quarter, missing the Zacks Consensus Estimate of $0.04 million. Revenues were down 27% year over year. Quarter in Detail Research & development (R&D) expenses were $52.3 million, down 35% from the year-ago quarter's level. General and administrative (G&A) expenses declined 9% year over year to $17.3 million. Allogenehad $397.3 million of cash, cash equivalents and investments as of Mar 31, 2024, compared with $448.7 million as of Dec 31, 2023. In a separate press release, management announced that it is floating a secondary issue of nearly 38 million shares of its common stock to the public at an issue price of $2.90 per share, intending to raise around $110 million in gross proceeds. The issue will include participation from venture capital and investment management companies and the company's board of directors and executive management. This issue is expec
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $11.00 price target on the stock.MarketBeat
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation SummitGlobeNewswire
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
ALLO
Earnings
- 5/13/24 - Beat
ALLO
Sec Filings
- 6/10/24 - Form 8-K
- 6/7/24 - Form 4
- 6/7/24 - Form 4
- ALLO's page on the SEC website